Characterization of Small Molecules and Peptides
Nuclear magnetic resonance (NMR) spectra were recorded on Varian Unity 400, Unity Inova 500, or Varian VXR 500 spectrometers. Small molecules (MW < 1000 Da) were analyzed by electrospray ionization/time-of-flight (ESI-TOF) mass spectrometry on a Waters Quattro II quadrupole spectrometer. Peptides (MW > 800 Da) were analyzed by matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) mass spectrometry on a Bruker UltrafleXtreme spectrometer using a matrix solution consisting of saturated α-cyano-4-hydroxycinnamic acid in 1:1 H 2 O/MeCN with 0.1% TFA. For larger peptides (MW>5000, or for endoproteinase digested mixtures), 3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid (sinapic acid) dissolved in 1:1 H 2 O/MeCN with 0.1% TFA was used as matrix. For smaller peptide fragments (500-1000 Da), MALDI-TOF analysis was performed with 2,5-dihydroxybenzoic acid (DHB) dissolved in 1:1 H 2 O/MeCN with 0.1% TFA. ESI-MS on peptides and their tandem MS analysis was carried out with a Synapt Waters G1 system. Samples were separated by liquid chromatography using a Phenomenex Jupitar C 18 300a column using an elution gradient of 3% solvent A, 97% solvent B to 40% solvent A, 60% solvent B over 20 min at a flow-rate of 0.2 mL/min (solvent A: 99.9% acetonitrile, 0.1% formic acid, solvent B: 0.1% formic acid in 99.9% water). For analysis of larger framents (MW>4000), an elution gradient of 3% solvent A, 97% solvent B to 70% solvent A, 30% solvent B over 20 min was used. The LC-system was directly connected to the MS chamber, where ESI was used to analyze samples, using Glu-1-Fibrinopeptide B (Glu-Fib) as external calibrant.
Small Molecule Synthesis Materials and purifications
Standard Fmoc-amino acids and resins, Boc-protected Cys and peptide coupling reagents-1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo [4,5-b ]pyridinium 3-oxid hexafluorophosphate (HATU), 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU), (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) , N,N'-diisopropylcarbodiimide (DIC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), 1-hydroxy-7-azabenzotriazole (HOAt) and 1-hydroxybenzotriazole (HOBt) were purchased from ChemImpex. [2, 3, H]-L-Ser was purchased from Cambridge Isotope Laboratories, and [2, H]-L-Thr was purchased from CDN-isotopes. Chitin resin was purchased from New England Biolabs. Dimethylformamide (DMF), dichloromethane (DCM), tetrahydrofuran (THF), methanol, and 1,4-dioxane were purchased at reaction grade from Fisher Scientific and dried via a solvent dispensing system prior to use. Other chemical reagents and reaction-grade solvents were purchased from Sigma Aldrich or Alfa Aesar and used without further purification. All reactions and chromatography fractions were monitored by thin layer chromatography (TLC) on silica-gel-coated glass plates with a F254 fluorescent indicator. Visualization was achieved by UV absorption by fluorescence quenching or permanganate stain (1.5 g KMnO 4 , 10 g K 2 CO 3 , 1.25 mL 10% NaOH in 200 mL of H 2 O), or ninhydrin stain (0.2% ninhydrin in EtOH) for visualizing compounds with free amines. For visualizing compounds with free carboxylic acids, bromocresol green (0.04% in EtOH) was used. Flash chromatography was performed using Silicycle SiliaFlash P60, 230-400 mesh silica gel.
Synthesis of building block 6 used to introduce a C-terminal alkyne
Compound 26. In a round bottom flask, 3-butyn-1-amine hydrochloride (0.21g, 1.99 mmol) was dissolved in 30 mL of DCM and neutralized with DIPEA (0.38 mL, 2.2 mmol). To the reaction mixture, Boc-L-cystine was added (0.44 g, 1 mmol), followed by EDC-HCl (0.39 g, 2.01 mmol) and HOAt (0.27 g, 2.02 mmol) and the reaction mixture was stirred at room temperature for 30 h. The reaction mixture was washed with sodium bicarbonate (1 x 15 mL), 10% citric acid (1 x 15 mL), and brine (1 x 15 mL), respectively. All aqueous layers were back-extracted with DCM (1 x 10 mL). The organic layers were collected, dried over sodium sulfate and concentrated to yield 26 (0.42 g, 77%). Compound 27. Compound 26 (0.42 g, 0.79 mmol) was suspended in 6 mL of dry DCM to form a milky suspension. To this suspension, 6 mL of trifluoroacetic acid (TFA) was added when a clear yellowish solution formed, which was stirred at room temperature for 1 h. TFA was then evaporated using a stream of N 2 . The residue was dissolved in water and lyophilized to yield 27 as white fluffy solid (0.34 g, 95%). Scheme for synthesis of Cys(o-NO 2 Bn) building blocks 36 5, 6 and 38 06 mmol) and Na 2 CO 3 (0.25 g, 2.36 mmol) was dissolved in 3 mL of H 2 O. Fmoc-OSu (0.75 g, 2.22 mmol) dissolved in 4 mL of dry dioxane was stirred in an ice-bath, and the amino acid solution was added slowly to the dioxane solution. The ice-bath was removed and the reaction was stirred for 20 h to form a milky suspension. The solvent was then removed on a rotary evaporator, and the residue was dissolved in H 2 O (20 mL) to generate a colorless solution. 10% citric acid was used to acidify the solution to pH 4.0, when a thick white solution formed. The aqueous layer was extracted with EtOAc (10 x 25 mL) and the organic layer was washed with brine (1 x 50 mL) and concentrated on a rotary evaporator followed by drying using a vacuum pump to generate a white solid, which was carried over to the next step without purification. Yield (crude): 0.97 g (calculated 0.71 g)
Compound 44. Compound 43 (0.97 g) was suspended in a solution of NaHCO 3 (0.18 g, 2.1 mmol) in 6 mL of H 2 O. The suspension was stirred under N 2 and to it, 13 mL of dry DCM was added, while stirring vigorously. Aliquat-336 (0.96 mL, 2.1 mmol) was added followed by allyl bromide (1.3 mL, 15 mmol) and then the reaction was continued to be stirred vigorously for 22 h. The reaction mixture was then diluted with 15 mL of H 2 O and extracted with DCM (4 x 20 mL). The organic layers were collected, washed with brine (1 x 20 mL), dried over Na 2 SO 4 and concentrated on a rotary evaporator to generate a pale-yellow oil. The crude mass was purified by flash chromatography (SiO 2 , 30% EtOAc in hexanes) to generate 44 as a white solid upon concentrating on a rotary evaporator. R f 0.21 (30% EtOAc in hexanes). Yield: 0.59 g (75%). 4 (0.05 g, 0.04 mmol) was added followed by N-methyl aniline (0.07 mL, 0.65 mmol) as a solution in 3 mL of dry THF and the reaction was stirred for 2.5 h. The reaction mixture was diluted with 100 mL of EtOAc and washed with brine (2 x 30 mL). The aqueous layer was extracted with EtOAc (5 x 25 mL) and concentrated on a rotary evaporator and dried using a vacuum pump. The product was used without further purification. HRMS (ESI) calculated for C 38 H 31 D 2 NO 5 Na (M+Na + ) 608.2380, observed 608.2378.
Solid Phase Peptide Synthesis (SPPS) General methodology
The automated peptide coupling was performed on a CEM Liberty microwave peptide synthesizer using standard Fmoc protected amino acids, 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) as activator, 2 M N,N-diisopropylethylamine (DIPEA) in N-methyl-2-pyrrolidone (NMP) as the activator base, 20% piperidine in dimethylformamide (DMF) as the deprotection agent and 90/8/2 DMF/acetic anhydride/DIPEA as the capping agent. Coupling of each amino acid in the microwave synthesizer occurred at 75 °C except for Cys and His residues for which coupling was performed at 50 °C to prevent racemization. Typically each residue was double coupled followed by a capping step, unless otherwise noted. Coupling of any synthesized non-proteinogenic amino acid residues and the azide linker at the N-terminus was performed manually using either diisopropyl carbodiimide (DIC) as the coupling agent with 1-hydroxy-7-azabenzotriazole (HOAt) as the racemization suppressant, or HCTU as activator. Unless otherwise stated, manual couplings were performed as follows. Fmoc deprotection was performed using 20% piperidine in DMF while sparging the resin with N 2 for agitation (2 x 5 min). After draining the reaction vessel, the resin was washed with DMF (6 x 30 s). The appropriate moiety to be coupled (4 equiv.) was dissolved in DMF (5-10 mL) and pre-activated with DIC/HOAt (4 equiv.) for 5 min, then added to the resin and the reaction was agitated by sparging with N 2 for 1 h. After draining the reaction vessel, the resin was washed as before. Kaiser test was performed to monitor the completion of coupling and double coupling was performed as needed. The coupling of [2,3,3- were performed under optimized conditions using (7-azabenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP) as activator and HOAt as racemization suppressant using 2,4,6-collidine as base to prevent partial loss of the -deuterium during coupling. After the completion of SPPS, the resin was washed with ca. 5 mL of DMF (3 x 30 s) and then ca. 5 mL of DCM (3 x 30 s) and drained under vacuum to dry the resin. The cleavage of the synthesized peptide from the resin was performed in a cleavage cocktail of 95/2.5/2.5 TFA/triisopropyl silane/H 2 O for 1 h and then the solution was filtered though a fritted funnel and the filtrate was evaporated under a stream of N 2 to remove most of the TFA. Peptide was precipitated by adding 10-15 mL of cold diethyl ether to the solution. The mixture was centrifuged and the supernatant was discarded. The precipitate was dissolved in 50% MeCN, 0.05% TFA in H 2 O, flash frozen in liquid N 2 and lyophilized to generate white to pale yellow amorphous powder, which was stored at  20 °C.
Often, the free thiols were protected as ethylthio disulfide to increase the yield of CuAAC. Such protection was carried out in solution phase. HPLC purified peptide was dissolved in H 2 O and about 10 equiv. of 34 (2-(ethyldisulfanyl)benzo[d]thiazole) dissolved in 20-50 L of EtOH was added and the reaction was stirred at room temperature for 7 h. The reaction mixture was centrifuged and the supernatant was further purified by HPLC using methods described later.
Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was performed on an Agilent 1260 Infinity system with a Phenomenex Luna C 18 , a Waters Vydac C 18 , or a Waters Vydac C 4 column with a flow rate of 1 mL/min and a solvent gradient of 2-100% solvent A over 45 min. Preparatory RP-HPLC was performed on a Waters 600 system with a Phenomenex Luna C 18 or C 5 semipreparative column using a gradient of 2% solvent A to 67% solvent A in 30 min. Any change from these standard HPLC conditions is noted in the procedures. All HPLC solvents were filtered with a Millipore filtration system equipped with a 0.22 μm nylon membrane filter prior to use. HPLC solvent compositions: solvent A was 80% acetonitrile in water with 0.086% trifluoroacetic acid (TFA), solvent B was 0.1% TFA in water.
Peptide 2. H-Cys(Trt)-2-chlorotrityl resin (0.05 mmol) was used. All amino acids (0.25 mmol) were manually coupled using HCTU (0.25 mmol) as activator and DIPEA (0.5 mmol) as base, except for the deuterated Ser residues. All residues were double coupled (2 x 1 h coupling time) followed by capping procedure. Coupling of [2, 3, H]-Ser was performed using PyBOP (0.25 mmol) as activator, HOAt (0.25 mmol) as racemization suppressant, and 2,4,6-collidine as base, with a 3 h coupling time. Post cleavage from the resin, 54 mg of crude peptide was obtained. Of the crude peptide, 25 mg was purified in 7 injections by preparative RP-HPLC using the standard gradient to elute 2 with a retention time (R t ) of 15. Peptide 47. The first residue Glu was coupled manually to H-Cys(Trt)-2-chlorotrityl resin using DIC/HOAt chemistry in the absence of base. Compound 38 was used to manually install Cys3 with 4,5-dimethoxy-2-nitrobenzyl protection using DIC/HOAt chemistry. All other residues were coupled using a CEM microwave synthesizer. The final coupling of the N-terminal azide-containing moiety was performed as follows. The peptide-bearing 2-chlorotrityl resin (0.05 mmol) was placed in a 5 mL round bottom flask. To the resin, a solution of compound 7 (45 mg, 0.13 mmol, 2.6 equiv.) in 2 mL of dry DMF was added, followed by 50 µL of DIPEA (0.22 mmol, 4.5 equiv) and the reaction was stirred overnight for 15 h. The solution was drained over a fritted funnel and the resin was washed with DMF (3 x 30 s) and DCM (3 x 30 s). Standard cleavage conditions yielded 5.5 mg of crude product, which was purified using a Phenomenex Luna C 18 column using the standard gradient and flow-rate conditions as previously described to yield pure precursor peptide to 47 (1.1 mg) with a free Cys19. R t 22.7 min, eluting at 52% of solvent A. The peptide was reacted with 34 and further purified by RP-HPLC using the standard conditions to generate 47 eluting with a R t of 23. pre-swelled in DMF. To this mixture, DIPEA (0.23 mL, 1.3 mmol) was added and the reaction was stirred for 14 h under N 2 . The solution was drained through a fritted funnel and the resin was washed successively with 5 mL of DCM, MeOH and again DCM. Subsequent iterative Fmoc deprotection and amino acid coupling (DIC/HOBt chemistry) was carried out on 0.1 mmol of resin. Standard cleavage generated the precursor to 48 with a free thiol at Cys3. About 11 mg of crude peptide was purified by RP-HPLC using the standard conditions to generate pure precursor to 48 (3.6 mg), R t : 20.2 min, eluted at 46% solvent A. 
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The free thiol at the Cys3 was protected by reaction with 34 and the obtained peptide was purified by HPLC using a Phenomenex Luna C 18 column using the standard conditions to obtain pure 48 (2. Peptide 49. H-Cys(Trt)-2-chlorotrityl resin was used. The first residue Glu was coupled manually to H-Cys(Trt)-2-chlorotrityl resin using DIC/HOAt chemistry in the absence of base. All residues except Cys3 were coupled on the microwave synthesizer using the standard conditions. Cys3 was coupled manually using diisopropylcarbodiimide (DIC) as activator and HOAt as racemization suppressant. Standard cleavage generated the precursor to 49 with a free thiol at Cys3 and Cys19. Crude peptide (30.6 mg) was purified by RP-HPLC using the standard conditions to elute precursor to 49 (7.4 mg, R t 20.2 min, 46% solvent A). The precursor to 49 (4.2 mg) was reacted with 34 and the product was purified by RP-HPLC using the standard conditions to yield pure 49 (2. Peptide 50. Fmoc-Ala-Wang resin (0.1 mmol) was used. Each residue was triple coupled followed by capping on a microwave synthesizer except for the following. Cys21 with an o-nitrobenzyl protected thiol was installed by coupling 36 manually using HCTU as activator and DIPEA as base. Final coupling of 6-azidomethyl nicotinic acid (compound 8) was performed manually using the same chemistry. After cleavage of the peptide from the resin, the yield of crude peptide was 103 mg. Of the crude peptide, 59 mg was loaded onto a Phenomenex C 18 column in 5 injections and purified using the standard gradient to elude 50 with a R t of 21.1 min (48% solvent A Peptide 52. H-Cys(Trt)-2-chlorotrityl resin (0.05 mmol) was used. Each residue was double coupled followed by capping on a CEM microwave synthesizer except for the following. Peptide 53. Using similar chemistry as described for peptide 52, this peptide was synthesized from 0.05 mmol resin to yield 9.8 mg of crude peptide, which was purified using the standard conditions to yield 1.4 mg of pure peptide with unprotected Cys3 and Cys19 (R t 17.5 min, 40% solvent A). Compound 34 (2.22 mg, 9.8 mol) dissolved in 40 L of EtOH was added to the 5 mL of peptide solution (1.37 mg) and the reaction mixture was stirred for 12 h at room temperature. The reaction mixture was diluted with 3 mL of starting eluent for RP-HPLC (2% solvent A, 98% solvent D) and then centrifuged (15000 x g, 5 min) and the supernatant was purified by HPLC in two injections using the standard conditions to elute 53 with a R t of 21. 
Generation of the Alkyne Modified ProcA3.2 Leader Peptide
Peptide 56. An aliquot of BL21 (DE3) E. coli cells was transformed with pET15b plasmid encoding His 6 -ProcA3.2-leader-intein-CBD (CBD: chitin binding domain) and then the transformed cells were spread on a LB + ampicillin (100 g/mL) agar plate and incubated overnight at 37 °C. Cells from a single colony were used to innoculate two 25 mL LB + Amp (100 g/mL) cultures, which were incubated overnight. The starter cultures were used to innoculate 2 x 1.5 L cultures in LB + Amp (100 g/mL) and the cells were grown until the OD 600 nm for each set was ca. 0.6 when IPTG (final concentration 0.5 mM) was added and the cultures were incubated in a 18 °C shaker overnight (final OD 600 nm 2.5-3.0). The cells were harvested by centrifugation (10,500 x g, 30 min). The cell pellets were suspended in 40 mL of lysis buffer (50 mM HEPES, 500 mM NaCl, 1 mM EDTA, 0.1 % Triton-X, PMSF (dissolved in 20 mL of isopropanol, final concentration ca. 1 mM), TCEP-HCl (1 mM, pH-7.5) and the cells were lysed by sonication (4.4 s pulse, 9.9 s interval, 35% amplitude). The cell lysate was centrifuged (22800 x g, 30 min) and the supernatant was filtered through 0.45 m amicon filters. The chitin resin (NEB) was loaded into a column and equilibrated with column buffer (50 mM HEPES, 500 mM NaCl, 1 mM EDTA). To the resin, the cell lysate was applied and the column was shaken in the cold room (4 °C) on a rocker for 4 h to allow proper mixing. The cell lysate was allowed to drain from the resin at 2 mL/min. The resin was washed further with column buffer (ca. 400 mL at 2 mL/min). Cleavage buffer (40 mL) consisted of column buffer containing MESNa (50 mM), TCEP-HCl (5 mM), compound 27 (60 mg, ca. 2 mM), and the pH was adjusted to 7.5. The cleavage buffer was added to the resin and the column was rocked for 16 h, after which the buffer was eluted. The resin was washed with 20 mL of column buffer and the washing along with the eluted cleavage buffer was concentrated on 3000 Da MWCO Amicon filter (4000 x g, 45 min) and the concentrated peptide was desalted on a C 4 Generation of ProcA2.8 WT Leader-AlaAla-MESNa Thioester Peptide 1. E.coli BL21(DE3) cells were transformed with pTXB1 plasmid encoding His 6 -tag-ProcA2.8 leaderAlaAla-intein-chitin binding domain, and the cells were spread on a LB + Ampicillin (100 g/mL) agar plate and incubated overnight at 37 °C. Cells from a single colony were used to innoculate two 25 mL LB + Amp (100 g/mL) starter cultures, which were incubated overnight. The starter culture was used to inoculate 5 L (2 x 1.5 L, and 2 x 1 L) LB + Amp (100 g/mL) medium. The cultures were shaken at 37 °C to an OD 600nm of ca. 0.6. After cooling the cultures to room temperature, IPTG (final concentration: 0.5 mM) was added to induce the cells and the cells were shaken at 18 °C for 17 h. The cells were harvested by centrifugation (10,500 x g, 20 min) and frozen at 80 °C until further use. The cell pellet (from 2.5 L culture) was thawed on ice and 30 mL of lysis buffer [NaP i (50 mM, pH 7.0), NaCl (500 mM), and TCEP (1 mM)] was added and the cells were homogenized. Cells were then lysed by sonication (4.4 sec pulse, 9.9 sec interval, 35% amplitude) on ice. The cells were centrifuged (22,800 x g, 30 min) and the supernatant was filtered through a 0.45 mfilter. The filtered supernatant was loaded onto a column packed with chitin resin (25 mL) equilibrated with column buffer [NaP i (50 mM, pH 7.0), NaCl (500 mM)]. The column was shaken on a rocker in a cold room (4 °C) for 2 h. The slurry was drained (1 mL/min) and the column was then washed with 250 mL (~10 CV) of column buffer. To the resin, 30 mL of cleavage buffer (column buffer + 50 mM MESNa) was applied and the column was shaken overnight on a rocker at 4 °C. The eluent was collected (~35 mL) and acidified to 0.1 % TFA to lower the pH (~4), desalted on a C 4 SPE column and eluted with 80% MeCN, 0.1% TFA in H 2 O and lyophilized. The lyophilized peptide was dissolved in 15 mL of starting eluent: 2% solvent A (80% MeCN, 0.086% TFA in H 2 O), 98% solvent D (0.1% TFA in H 2 O) and then purified in 5 injections using a C 5 -Phenomenex semi-prep column using a flowrate of 7 mL/min. Elution gradient: 2% A to 67% solvent A over 30 min. Product eluted with a R t of 21.9 min -22.9 min (50% -52% solvent A). Yield: 9 mg (from 2. If after 1 h, a significant fraction of starting peptide remained, further addition of activated catalyst followed by stirring at room temperature under N 2 was performed. The crude reaction mixture was desalted using a C 4 solid phase extraction (SPE) column and lyophilized.
The thioethyl protection group was removed from Cys by dissolving the semi-synthetic precursor in 3 mM TCEP-HCl in 2 mM Tris buffer, pH 7.5, and stirring at room temperature for 3 to 5 h, unless otherwise noted. The reaction mixture was purified using a Phenomenex Luna C 5 column using a gradient of 2% to 67% solvent A in 30 min with a flow rate of 7 mL/min using a Waters HPLC instrument to generate the precursor peptide with one free Cys.
Peptide 9.
Peptide 57 (0.63 mg, 0.07 mol) and peptide 53 (0.17 mg, 0.07 mol) were mixed and to the reaction was added four batches of 40 L of freshly prepared catalyst solution with an interval of one hour between each addition. The crude reaction mixture was desalted using a C4 SPE column to yield peptide precursor to 9 with thioethyl protected Cys residues. The peptide was reduced with TCEP and purified S14 by RP-HPLC using the standard conditions to generate peptide 9 (0.2 mg, 26%). MALDI-TOF MS calculated 11336 (M+H + ), observed 11339. Peptide 11. Peptide 57 (0.95 mg, 0.1 mol) and peptide 49 (0.37 mg, 0.15 mol) were mixed and to the reaction was added two batches of 40 L of freshly prepared catalyst solution with an interval of one hour. The reaction was stirred for 2 h after the second addition of catalyst solution. The reaction mixture was desalted using a C 4 SPE column to yield peptide precursor with thioethyl protected Cys residues, which was reduced with TCEP and purified by RP-HPLC using a C 5 Phenomenex column, the standard gradient, and a 8 mL/min flow rate. The product 11 eluted with a R t of 21.4 min. MALDI-TOF MS calculated 11410, observed 11396. Yield: 0.6 mg (50 %).
Peptide

10.
Peptide 57 (0.46 mg, 0.05 mol) and peptide 52 (0.13 mg, 0.05 mol) were mixed and to the reaction was added three batches of 40 L of freshly prepared catalyst solution with an interval of 1 h between additions. The product was reduced
Peptide
12.
Peptide 57 (0.73 mg, 0.08 mol) and peptide 54 (0.24 mg, 0.1 mol) were mixed and to the reaction was added three batches of 40 L of freshly prepared catalyst solution with an interval of 1 h after each S15 addition. The reaction mixture was desalted, reduced with TCEP and purified by RP-HPLC using a C 5 Phenomenex column using a gradient of 2% to 100% solvent A over 45 min with a flow rate of 8 mL/min. The product eluted with a R t of 21 min, 48% solvent A. Yield: 0.42 mg (45%)
were mixed and to the reaction was added three batches of 40 L of freshly prepared catalyst solution with an interval of one hour between additions. The reaction was stirred for another 2 h after the third addition of catalyst solution. The reaction mixture was desalted, reduced with TCEP and purified by RP-HPLC using a C 5 Phenomenex column using a gradient of 2% to 100% solvent A over 45 min with a flow rate of 8 mL/min. The product 25 eluted with a R t of 21.1 min (48% solvent A). Yield: 0.56 mg (54%).
Peptide 14.
Peptides 57 (440 µg, 0.05 µmol) and 47 (130 µg, 0.05 µmol) were mixed together and two batches of 40 L of catalyst solution were added. The reaction mixture was desalted using a C 4 SPE column and lyophilized to generate precursor to 14 with thioethyl protected Cys19 (550 µg). The product was reduced with TCEP as described in General Methodology and further purified by RP-HPLC using the standard gradient to yield pure 14 (430 µg, 76%).
Peptide
15.
Peptide 57 (925 µg, 0.1 µmol) was mixed with 48 (320 µg, 0.13 µmol) and the two batches of 40 L of catalyst solution were added. The reaction mixture was desalted using a C 4 SPE column and lyophilized to yield crude precursor to 15 with thioethyl protected Cys3 (1.1 mg). MS (MALDI-TOF) indicated complete S16 conversion to product. The crude precursor to 15 was reduced with TCEP followed by RP-HPLC purification with a C 5 Phenomenex Luna column using the standard conditions to yield pure 15 (0.64 mg, 55%). R t 20.8 min, eluting at 47% solvent A. LR-MS (MALDI-TOF) calculated 11466 (M+H + Peptide 17. Peptide 57 (0.84 mg, 0.09 mol) and peptide 51 (0.36 mg, 0.14 mol) were mixed and three batches of 40 L of freshly prepared catalyst solution were added with an interval of one hour between additions. The reaction was stirred for 2.5 h after the third addition of catalyst solution. The reaction mixture was desalted using a C 4 SPE column to yield peptide precursor with thioethyl protected Cys, which was reduced with TCEP and purified by RP-HPLC using a C 5 Phenomenex column using the standard gradient and a 8 mL/min flow rate. The product 7 eluted with a R t of 21.4 min. MALDI-TOF MS calculated 11694, observed 11694. Yield: 0.52 mg (49%). 
Peptides Generated by Native Chemical Ligation
Purification of ProcM
The enzyme was overexpressed as reported earlier, with the exception that ProcM gene was cloned in a pRSFDuet vector instead of pET28b vector as originally reported. 9 After IMAC purification, ProcM was was further purified by size-exclusion chromatography (Superdex 200 resin, 120 mL column volume) using an FPLC (Akta P-920) and was obtained as a mixture of monomer and dimer/trimer; when separated, both were active. A brief procedure for ProcM purification is as follows. All steps were carried out in the cold room (4 °C) or on an ice-bath. Crude cell lysate (from 3 L culture) was suspended in 50 mL of ProcM start buffer (1 M NaCl, 20 mM Tris, pH 8.0), along with protease inhibitor (Roche cOmplete), and lysed by passing through a French-press and centrifuged (14,000 x g, 30 min). The supernatant was filtered through 0.45 m syringe filters and loaded onto a Ni-HiTrap column equilibrated with 4 column volumes (CV) of ProcM start buffer. The column was washed by 6 CV of ProcM wash buffer (1 M NaCl, 20 mM Tris, pH 8.0, 30 mM imidazole) and then the column was attached to the FPLC and the protein was eluted using wash buffer and elute buffer (EB: 1 M NaCl, 20 S18 mM Tris, pH-8.0, 200 mM imidazole). The following gradient was applied: 6 CV of 5% EB, then 6 to 10 CV of 5% to 40% EB, 10 to 12 CV: 40% to 100% EB, 12 to 18 CV: 100% EB. The fractions containing the protein were 8 CV to 14 CV, as monitored by absorbance at 280 nm. The purified protein was concentrated using an Amicon ultrafilter (50 kDa cut-off) and desalted/purified by gel-filtration on FPLC (using ProcM start buffer (1 M NaCl, 20 mM Tris, pH-8.0) at a flow rate of 1 mL/min. The aggregated protein (40 mL to 55 mL elution volume) was discarded and the monomer and oligomer fractions (60 mL to 85 mL elution volume) were collected and concentrated using 30 kDa cut-off Amicon centrifugation filters to a concentration of ca. 60 M to 250 M, depending on the batch.
Purification of ProcM in D 2 O Containing Buffer
The monomer-oligomer mixture obtained from size-exclusion chromatography (15 mL), as mentioned in the previous section, was concentrated to 1 mL by ultrafiltration (2,300 x g), and then 10 mL of 1 M NaCl, 50 mM HEPES, pH 8.0 in D 2 O was added and the protein was again concentrated to 1 mL by centrifugation. Further addition of 10 mL of 1 M NaCl, 50 mM HEPES, pH 8.0 in D 2 O to the concentrated protein solution followed by ultrafiltration to generated a stock of 84 M ProcM (10 mg/mL, D 2 O:H 2 O over 99:1). The solution was aliquoted in fractions of 25 L.
General Procedure for Heterologous Expression of Precursor Peptides
ProcA2.8, ProcA3.3, ProcA2.8-S9T, ProcA2.8-S13T, and ProcA3.3-T11S were generated by the following general methodology. E. coli BL21 cells were transformed with pET-15b plasmid encoding the desired gene and the transformed cells were spread on an LB + Amp (100 g/ mL) agar plate and the plate was incubated overnight at 37 °C. Cells from single colonies were used to inoculate starter cultures (2 x 25 mL) in LB + Amp (100 g/mL) and incubated at 37 °C in a shaker for 16 h. The starter cultures were centrifuged (4,300 x g, 10 min) and the LB media was replaced with fresh LB and was used to inoculate a large scale culture (2 x 1.5 L) of LB + Amp (100 g/mL). The flasks were incubated at 37 °C with shaking until an OD 600 nm of 0.6 was reached (typically 3-4 h). The culture was induced with IPTG (0.5 mM final concentration) and further incubated at 37 °C in a shaker for 3 h when a final OD 600 nm in the range of 1.0 -2.5 was reached. The cells were harvested by centrifugation (10,500 x g, 15 min), flash frozen and stored at 80 °C for future use. The cells were thawed on ice and suspended in 30 mL of LanA start buffer (20 mM NaH 2 PO 4 , pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol) and lysed by sonication (4.4 s pulse, 9.9 s off, 35% amplitude, pulse time 6 min). The cell lysate was centrifuged (22,800 x g, 30 min) and the supernatant, referred as 'soluble fraction' was filtered through a 0.45 mfilter. The cell residue was resuspended in 25 mL of Lan buffer 1 (6 M guanidine hydrochloride, 20 mM NaH 2 PO 4 , pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole), sonicated, and centrifuged as described above. The supernatant referred to as 'insoluble fraction' was filtered through a 0.45 mfilter. A 5 mL Ni-His trap column charged with NiSO 4 was equilibrated with two column volumes (CV) of LanA start buffer after which the 'soluble fraction' was loaded at flow rate of 2 mL/min. The column was then equilibrated with two CV of Lan buffer 1 and loaded with the 'insoluble fraction' at 2 mL/min. The column was washed with two CV of Lan buffer 1 and two CV of Lan buffer 2 (4 M guanidine hydrochloride, 20 mM NaH 2 PO 4 , pH 7.5 at 25 °C, 300 mM NaCl, 30 mM imidazole) and eluted with LanA elution buffer (4 M guanidine hydrochloride, 20 mM Tris, pH 7.5 at 25 °C, 100 mM NaCl, 1 M imidazole) where 10 mL of the elution fraction was collected as fraction 1 and 5 mL was collected as fraction 2. Both fractions were desalted using C 4 SPE columns and lyophilized.
ProcA2.8 precursor peptide:
The desalted peptide was injected onto a Phenomenex Luna C 5 column and eluted with a gradient of 2% to 67% solvent A in 30 min, and a flow rate of 7 mL/min. R t 22 -24.5 min. 13 , and allowed to react at room temperature for 16-20 h. ProcM was removed from the assay mixtures by ultrafiltration through 50 kDa molecular weight cut-off filters (Amicon) by centrifugation (14,000 x g, 10 min). To improve recovery of processed peptide, water (50 L) was added to the retentate, and the solution was filtered by centrifugation (14,000 x g, 10 min). This process was repeated twice. The combined filtrates were collected and desalted on a C 4 solid phase extraction column (Vydac BioSelect). The SPE column was first wetted with 2 column volumes (CV) of 80% MeCN in H 2 O. The column was washed with 0.1% trifluoroacetic acid (TFA) in H 2 O (3 CV) and then the assay product was diluted with 0.1 % TFA in H 2 O (1:1) and passed through the column. The column was further washed with 0.1 % TFA in H 2 O (3 CV) and finally the product was eluted with 80% MeCN in H 2 O (2 x 1 mL). The eluents were lyophilized to yield the processed peptide with selectively formed thioether rings and one o-nitrobenzyl protected cysteine.
The lyophilized peptide obtained from the previous step was dissolved in 0.1% formic acid in H 2 O and subjected to UV (365 nm) irradiation for 4 h, using a portable UV lamp source (Spectroline ENF-240C). After irradiation, the solution was lyophilized.
General Procedure for Probing Enzymatic vs. Non-Enzymatic Cyclization
Non-enzymatic cyclization: The peptide obtained from the previous step was incubated at room temperature in solution containing all components used in standard ProcM assay except the enzyme. A typical non-enzymatic assay solution comprised HEPES (50 mM), ATP (10 mM), TCEP (0.2 mM), MgCl 2 (10 mM), and substrate (ca. 50 M) with a final pH of 8.0. A second assay was conducted at higher pH 8.5, and assays were kept at room temperature for 16 h.
Enzymatic cyclization: Control assays of the substrate generated in the previous step in the presence of ProcM (20 M) were also set up under identical conditions and incubated at room temperature for 16 h. The enzymatic and the non-enzymatic cyclization assays were carried out and analyzed in parallel.
To probe the extent of cyclization of the second thioether ring, iodoacetamide (IAA) assays were performed on the products of the non-enzymatic and the enzymatic assays. The pH of the assay solution was raised to 8.5 by the addition of NH 4 HCO 3 buffer (100 mM), TCEP (0.5 mM) and excess IAA (ca. 20 mM) was added, and the assay was incubated at room temperature for 3 h, before analysis by MALDI-TOF MS.
General Procedure for the Incorporation of Deuterium in the ProcM Product
ProcM assays were conducted at room temperature for 20 h with the following compositions in D 2 O: HEPES (50 mM, pH 8.0), TCEP (0.5 mM), ATP (10 mM), MgCl 2 (10 mM), ProcM (10 M), and (50 M) substrate. ProcM was removed by centrifugation through Amicon 50 kDa MWCO filters (14,000 x g, 20 min), and the flow through was desalted using C 4 SPE column and lyophilized. MALDI-TOF analysis demonstrated the incorporation of one deuterium per Lan/MeLan.
General Procedure for D-H Exchange Assays
Each lyophilized deuterium labeled peptide was dissolved in H 2 O and ProcM assays were conducted at room temperature for 20 h in aqueous solution with the following composition: HEPES (50 mM, pH 8.0), TCEP (0.5 mM), ATP (10 mM), MgCl 2 (10 mM), ProcM (10 M), and substrate (50 M). Control assays in which the substrates were treated with all components except ProcM were also performed. MALDI-TOF MS analysis was carried out after digesting the peptide with GluC by adding 1 L of GluC (20 g/L) or 1 L of LysC (30 U/mL) to 20 L of assay mixture. Simulation of extent of exchange was carried out using mmass software. The assays were kept at room temperature and after each time-point, one assay sample was filtered through 50 kDa cut-off filters by centrifugation to remove ProcM (14,000 x g, 10 min). The chosen time-points were 10 min, 30 min, and 1 h. An assay with higher ProcM concentration (10 M), and longer incubation (9 h) was also performed.
Substrates assembled by expressed protein ligation (EPL) with deuterium labeled Ser/Thr were treated with ProcM under the following conditions unless otherwise noted. A typical assay volume of 20 L contained HEPES (50 mM, pH 8.0), ATP (10 mM), TCEP (0.5 mM), MgCl 2 (10 mM), ProcM (2 M), and substrate (100 M). The assays were kept at room temperature and after each time-point, one assay sample was filtered through a 50 kDa cut-off filter by centrifugation (14,000 x g, 10 min). The chosen time-points were 5 min, 10 min, and 30 min.
The filtered peptides were digested with endo-proteinase GluC (1 g/L) or LysC (0.3 U/L), as noted, and then analyzed by MALDI-TOF MS and ESI-MS.
General Procedure for Trapping Partially Cyclized Species to Probe Directionality of Cyclization
ProcA precursor peptides were modified by ProcM at room temperature in solutions containing HEPES (50 mM, pH 8.0), ATP (10 mM), TCEP (1.0 mM), MgCl 2 (10 mM), ProcM (5 M), and substrate (100 M). After each time point (15 min, 30 min, 1 h), 100 L aliquots were taken and filtered through 50 kDa cut-off filters by centrifugation (14,000 x g, 10 min). The filtrates were digested with GluC (1g/L) for 1 h. The endoproteinase digested filtrate (16 L) was then diluted with 24 L of 200 mM NH 4 HCO 3 (pH 8.8), 1 L of TCEP (10 mM), and 10 L of iodoacetamide (10 mg/mL) was added. The solution was incubated at room temperature for 2 h. The samples were frozen and stored at 80 °C, until analyzed by ESI LC-MS and tandem MS. Prior to loading the samples onto the LC system, 0.1% formic acid was added (1:1) to lower the pH to ca. 6.5.
Molecular Cloning of His-Tag-ProcA3.2-Leader-Intein-CBD
The DNA sequence encoding the ProcA3.2 leader peptide was cloned between NdeI and SapI restriction sites of a pTXB1 vector to position the ProcA3.2 leader gene before the gene encoding intein and chitin binding domain (CBD). pET28b encoding the ProcA3.2 precursor peptide gene was used as template. 9 The primers were 5'-GGT GGT CAT ATG ATG TCA GAA GAA CAA CTC AAG GCA TTT ATT G-3' (ProcA3.2-leader_NdeI_FP), and 5'-GGT GGT TGC TCT TCC GCA TCC CCC AGC CAC ACC TTC 3' (ProcA3.2-leader_SapI_RP) . The generated pTXB1 plasmid encoding 'ProcA3.2-leader_intein_CBD' was used as template to insert 'ProcA3.2-leader_intein_CBD' between the NdeI and BamHI restriction sites of a pET15b plasmid after the DNA sequence encoding the His-tag. The primers used were 5'-GGT GGT CAT ATG TCA GAA GAA CAA CTC AAG GCA TTT ATT G-3' (His-tag_ProcA3.2-leader_intein_CBD_NdeI_FP) and 5'-GGT GGT GGA TCC TCA TTG AAG CTG CCA CAA GG-3' (His-tag_ProcA3.2-leader_intein_CBD_BamHI_RP) to generate the final pET15b construct of 'His-tag_ProcA3.2-leader_intein_CBD'.
Mutagenesis of ProcA Genes
The first residue of the core peptide is designated as 1 and the last residue of the leader peptide is designated as 1. Mutation of the C-terminal Gly of ProcA3.2 leader to Lys in 'His-tag_ProcA3.2-leader_intein_CBD' was performed by QuikChange site directed mutagenesis. The primers were 5'-GAA GGT GTG GCT GGG AAA TGC ATC ACG GGA GAT G-3' (His-tag_ProcA3.2-leader-G1K_intein_CBD_FP) and 5'-CCC AGC CAC ACC TTC CAG CTC ATC ATC-3' (His-tag_ProcA3.2-leader-G-1K_intein_CBD_RP), which were used to generate pET15b construct encoding 'Histag_ProcA3.2-leader-G1K_intein_CBD'. The ProcA2.8 and ProcA3.3 Ser/Thr mutants were generated using the following primers by QuikChange site directed mutagenesis based on a modified protocol. Highly conserved leader peptide and diverse core peptides are presented. Of the 29 substrates, the 16 investigated to date are all substrates of ProcM. . Scheme for generation of ProcA leader peptide with a C-terminal alkyne. The leader peptide was expressed as a fusion protein with an intein and chitin binding domain at its C-terminus. Chitin resin was used to affinity purify the fusion protein, which was cleaved from the resin by transthioesterification with MESNa. The C-terminal MESNa thioester of the leader peptide formed in-situ reacts with 6 (expressed protein ligation) to generate the leader peptide with a C-terminal alkyne. The introduced cysteine was capped with iodoacetamide. Figure S8 . GC-MS analysis illustrating that triazole-linked ProcA2.8 11 is processed by ProcM to generate Lan and MeLan with the same stereochemistry as in wt peptide. ProcM modified peptide was hydrolyzed in acid and the resulting amino acids were derivatized as reported previously (also as previously reported, this procedure leads to partial epimerization of Lan). 13 The derivatized material was analyzed by GC-MS using a chiral structure phase as previously reported. , and that the same B-ring undergoes exchange faster than the A-ring when starting with fully cyclized peptide (shown on the left and right). In this model, the transition state energies for forming the A-or B-ring are independent on whether the other ring is already installed. In panel A, the transition state energies for cyclization of the A-ring (or B-ring) are drawn the same regardless of whether the B-ring (or A-ring) is already formed. The energies for the peptides containing either the A-or B-rings are also arbitrarily drawn the same. In panel B, the barriers for cyclization of the A-and B-rings are drawn as independent of whether the other ring is already formed or not, but the transition state energies are not identical. Once again this scenario can explain the experimental data, but the difference with panel A is that product formation will preferentially go through the left hand pathway.
In either panel A or B, in the forward direction (i.e. starting with uncyclized peptide) only the intermediate with the B-ring can be detected and in the reverse direction, exchange of the proton in the B-ring will be faster than that of the A-ring. It has to revert to the linear peptide, which in a much slower process forms the A-ring. Formation of the A-ring is then followed by fast closure of the B-ring. This scenario is reminiscent of the Curtin-Hammett principle in which two compounds are in equilibrium and for which the ratio by which the starting compound follows the two pathways to product is determined by the difference in the transition state energies.
